Source: Chang L. et al., Frontiers in Pharmacology, 2022, 10.3389/fphar.2022.1026182
The objective of the study is to characterize the pharmacokinetics, tissue distribution, metabolism, and excretion of the peptide BPC-157 (Body Protection Compound-157) in various animal models. Additionally, its safety, tolerability, and bioavailability were evaluated across different routes of administration.
BPC-157 is a gastrointestinal peptide that has been of scientific interest due to observed effects in preclinical models related to tissue repair, angiogenesis, and modulation of inflammatory processes. The present study aims to provide objective pharmacokinetic data and information on the safety profile of the molecule under experimental conditions.
Type: experimental preclinical study
Models: Sprague-Dawley rats and Beagle dogs
Doses and administration:
IV, intravenous: 0.4 mg/kg
IM, intramuscular: 0.4 mg/kg
PO, oral: 0.4 mg/kg
Duration: monitoring up to 24 hours post-administration
Parameters measured:
Plasma concentrations of BPC-157
Tissue distribution, including liver, kidneys, muscle, and stomach
Metabolites and main elimination pathways
Bioavailability with IM and PO administration relative to IV administration
Pharmacokinetics and Distribution
The elimination half-life is approximately 25–30 minutes after IV administration.
Following intramuscular administration, reported bioavailability was 45–51% in dogs and 14–19% in rats.
Peak concentrations are reached within 5–15 minutes after IV administration and 30–60 minutes after IM administration.
BPC-157 is distributed mainly in the liver, kidneys, muscle tissue, and stomach.
Metabolism and Elimination
The molecule is metabolized into shorter peptide fragments and amino acids through the action of plasma peptidases.
Excretion occurs mainly via urine and bile.
Safety
No toxic effects or significant changes in biochemical parameters were observed during the study period.
Good local tolerability was reported with IM and PO administration.
BPC-157 shows a short half-life but good tissue distribution and a favorable safety profile in the animal models studied.
The data support the potential for systemic administration via IM and PO routes in an experimental context.
No evidence of toxicity or accumulation was observed with a single dose.
The results support the need for further clinical research related to regeneration, recovery, and safety.
The study was conducted only on preclinical animal models and does not include human data.
The follow-up duration was limited to 24 hours, so chronic use was not evaluated.
The study focused on pharmacokinetics, distribution, and safety, rather than direct efficacy.
BPC-157 shows a good tolerability profile in animals at the doses studied.
The data position it as a suitable candidate for further experimental research related to tissue regeneration, recovery after injury, and inflammatory processes.
Additional human studies are needed to determine applicability, dosing regimens, long-term safety, and the actual efficacy of the molecule in a clinical context.